Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, coagulopathies and disorders of the central nervous system. Our most clinically advanced product candidates are derived from our proprietary PharmacoSurgery...

From the outset, Omeros recognized that a combination of agents acting on multiple molecular targets may be required for optimal therapeutic effect. Our PharmacoSurgery product candidates are designed to modulate the molecular mechanisms of pathologic conditions rather than just treating their sympt...

Omeros is developing proprietary compositions that include peroxisome proliferator-activated receptor gamma (PPAR) agonists for the treatment and prevention of addiction to substances of abuse and other compulsive behaviors. Based on the previously unknown link between PPAR and addictive disorders t...

A discovery by researchers at the University of Leicester led to the identification of mannan-binding lectin-associated serine protease-2 (MASP-2), a novel pro-inflammatory protein target in the complement system. Omeros holds worldwide exclusive licenses to rights related to MASP-2, the antibodies ...

Terms of Use Welcome to Omeros Corporation's web site. The information provided on this site is for general informational and educational purposes only. The following Terms of Use apply to your use of this site and any of the content, materials or services provided in or through this site. Please re...